77 patents
Page 2 of 4
Utility
Method of Improving Sleep
8 Dec 22
The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).
Mihael POLYMEROPOULOS, Sandra SMIESZEK
Filed: 16 Aug 22
Utility
Method for Improving or Enhancing Cognition
1 Dec 22
Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual.
Mihael H. Polymeropoulos
Filed: 8 Aug 22
Utility
Tasimelteon Use In Treating Sleep Aberrations
3 Nov 22
The invention relates generally to circadian rhythm disorders and, more particularly, to the treatment or prevention of circadian rhythm disorders based on an individual's HCN1 genotype.
Mihael Polymeropoulos, Sandra SMIESZEK
Filed: 29 Jun 20
Utility
Treatment of Affective Disorders
8 Sep 22
Embodiments of the invention relate generally to the treatment of affective disorders and, more particularly, to the treatment of affective disorders in a patient of Majority Black African ancestry.
Mihael Polymeropoulos, Christos Polymeropoulos, Changfu Xiao
Filed: 26 May 22
Utility
Methods for the Administration of Iloperidone
18 Aug 22
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
Filed: 8 Apr 22
Utility
Use of Tradipitant In Motion Sickness
11 Aug 22
Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos
Filed: 28 Apr 22
Utility
Method of Treatment with Tradipitant
21 Jul 22
This application relates to a method of treatment with the NK-1 antagonist, tradipitant.
Mihael H. Polymeropoulos, Louis William Licamele
Filed: 6 Apr 22
Utility
Treatment of Circadian Rhythm Disorders
9 Jun 22
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 15 Feb 22
Utility
Treatment of Circadian Rhythm Disorders
2 Jun 22
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 15 Feb 22
Utility
Treatment of Circadian Rhythm Disorders
2 Jun 22
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 15 Feb 22
Utility
Method of Treatment
5 May 22
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
Christian Lavedan, Mihael H. Polymeropoulos
Filed: 14 Jan 22
Utility
Method of Treatment with Tradipitant
31 Mar 22
Disclosed herein is a method of treatment of gastroparesis and symptoms thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos, Gunther Birznieks, Changfu Xiao
Filed: 3 Dec 19
Utility
Genetic Markers for Enhancing Efficacy of Antipsychotic Treatment with Iloperidone
17 Mar 22
The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.
Mihael H. Polymeropoulos, Sandra Smieszek
Filed: 29 Nov 21
Utility
Highly Purified Pharmaceutical Grade Tasimelteon
10 Mar 22
A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Filed: 17 Nov 21
Utility
Method of Improving Sleep
10 Feb 22
The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).
Mihael POLYMEROPOULOS, Sandra SMIESZEK
Filed: 13 Feb 20
Utility
Method of Treatment
9 Dec 21
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions.
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Filed: 20 Aug 21
Utility
Treatment of Disorders with Tasimelteon
25 Nov 21
Tasimelteon improves sleep in individuals experiencing an advance in established bedtime.
Vasilios POLYMEROPOULOS, Christos POLYMEROPOULOS, Changfu XIAO, Mihael H. POLYMEROPOULOS
Filed: 4 Mar 19
Utility
Improving Sleep or Post-Sleep Performance
18 Nov 21
The invention relates generally to improving sleep, post-sleep performance, or both and, more particularly, to so improving without inducing post-sleep effects that would impair an individual's ability to operate machinery or a motor vehicle.
Mihael H Polymeropoulos, Christos Polymeropoulos, Changfu Xiao
Filed: 12 Sep 19
Utility
Treatment of Circadian Rhythm Disorders
28 Oct 21
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 6 Jul 21
Utility
Method of Treatment with Tradipitant
28 Oct 21
Disclosed herein is a method of treatment of gastric motility disorders and of improving gastric motility comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos, Gunther Birznieks
Filed: 8 Jul 21